Biopsy

Predicine and Merck KGaA, Darmstadt, Germany to Present Data at AACR - Advances in Liquid Biopsy Conference 2020

Retrieved on: 
Tuesday, January 7, 2020
Medicine, Clinical medicine, Liquid biopsy, Biopsy, Merck Group

Highlights of this study include:

Key Points: 
  • Highlights of this study include:
    The clinical feasibility of simultaneous multiparametric profiling using a combined cfDNA and cfRNA liquid biopsy approach for molecular characterization in advanced CRC.
  • cfRNA-derived variant detection confirms the variants originally detected in cfDNA test and validates the high specificity results for report interpretation.
  • "We are very delighted to work with Merck KGaA, Darmstadt, Germany, a precision medicine driven company.
  • Predicine has developed a breakthrough RNA- and DNA-based liquid biopsy technology for non-invasive cancer profiling, disease monitoring and assessing minimal residual disease.

Biopsy Devices (General Surgery) - Global Market Analysis and Forecast Model

Retrieved on: 
Tuesday, January 7, 2020
Medicine, Medical specialties, Clinical medicine, Biopsy, Breast biopsy

Biopsy Devices (General Surgery) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within General Surgery therapeutic area.

Key Points: 
  • Biopsy Devices (General Surgery) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within General Surgery therapeutic area.
  • Demand for the minimal invasive procedure has also contributed to the biopsy devices market.
  • - Annualized total Biopsy Devices market revenue by segment and market outlooks from 2015-2028.
  • - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Biopsy Devices market in the future.

Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers

Retrieved on: 
Monday, January 6, 2020
Medicine, Clinical medicine, Biopsy, Medical specialties, RTT, Liquid biopsy, Cancer, Molecular diagnostics, Skin biopsy

Moreover, the World Health Organization has estimated the number of new cancer cases to rise by 70% over the next 20 years.

Key Points: 
  • Moreover, the World Health Organization has estimated the number of new cancer cases to rise by 70% over the next 20 years.
  • For many years, tissue biopsy has been considered the gold standard for cancer diagnosis.
  • Amongst other promising diagnostic tools, liquid biopsy has emerged as a versatile and promising non-invasive cancer diagnostic tool.
  • One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for non-invasive cancer diagnostics.

Anixa Biosciences Announces Presentation at AACR Liquid Biopsies Conference

Retrieved on: 
Monday, January 6, 2020
Medicine, Clinical medicine, Medical specialties, RTT, Prostate cancer, Biopsy, Histopathology, Interventional radiology, Breast cancer, Cancer, Prostate cancer screening, Prostate-specific antigen

The presentation will review data related to Anixa's recently launched Cchek Prostate Cancer Confirmation test.

Key Points: 
  • The presentation will review data related to Anixa's recently launched Cchek Prostate Cancer Confirmation test.
  • The AACR conference takes place January 13 January 16, 2020 at the Hilton Miami Downtown in Miami, Florida and is designed to showcase the latest advances in liquid biopsies and how they may be translated into the clinic.
  • To date, Anixa has successfully used Cchek to detect the presence of 20 different cancers including lung, colon, breast and prostate.
  • On December 16, 2019, Anixa announced the commercial launch of the Cchek Prostate Cancer Confirmation test(Cchek PCC), thefirst test developed with the Cchek liquid biopsy technology.

DermTech’s Pigmented Lesion Assay (PLA) Receives Medicare Coverage

Retrieved on: 
Thursday, January 2, 2020
Genetics, Health, Oncology, Other Health, Biopsy, Interventional radiology

DermTech, Inc. (NASDAQ: DMTK) (DermTech), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that the Medicare Administrative Contractor Palmetto GBA MolDx (Palmetto) has issued a final local coverage determination for the Pigmented Lesion Assay (PLA).

Key Points: 
  • DermTech, Inc. (NASDAQ: DMTK) (DermTech), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that the Medicare Administrative Contractor Palmetto GBA MolDx (Palmetto) has issued a final local coverage determination for the Pigmented Lesion Assay (PLA).
  • Clinicians with sufficient skill and experience to decide whether a pigmented lesion should be biopsied may order the PLA test, with up to two (2) tests allowed per patient for each date of service.
  • For additional information on DermTech, please visit DermTechs investor relations site at: www.dermtech.com .
  • These forward-looking statements include, without limitation, expectations with respect to the performance, patient benefits and cost-effectiveness of DermTechs PLA.

Global Liquid Biopsy Market Report 2019 - World Market to Exhibit a CAGR of 23.31% During 2018-2024 - ResearchAndMarkets.com

Retrieved on: 
Monday, December 23, 2019
Health, Other Health, Medicine, Clinical medicine, Biopsy, Liquid biopsy

The "Global Liquid Biopsy Market - Forecasts from 2019 to 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Liquid Biopsy Market - Forecasts from 2019 to 2024" report has been added to ResearchAndMarkets.com's offering.
  • The growth in the market may be attributed to the rising patient population base owing to the rising prevalence of cancer.
  • Rising preference for the non-invasive procedures will also augment the growth of the liquid biopsy market during the given forecast period.
  • However unclear regulatory scenario pertaining to liquid biopsy along with unfavourable reimbursement policies might restrain the growth of the market during the given time frame.

Global Breast Biopsy Devices Market 2019-2023 | Evolving Opportunities with Argon Medical Devices, Inc. and Pfizer Inc. | Technavio

Retrieved on: 
Friday, December 20, 2019
Health, Oncology, Medical devices, Medicine, Medical specialties, Clinical medicine, Breast biopsy, Biopsy, Breast cancer, Stereotactic surgery, Mammotome, Prostate biopsy

Also, the paradigm shift toward the adoption of breast biopsy robot systems is anticipated to boost the growth of the breast biopsy devices market.

Key Points: 
  • Also, the paradigm shift toward the adoption of breast biopsy robot systems is anticipated to boost the growth of the breast biopsy devices market.
  • View the full release here: https://www.businesswire.com/news/home/20191219005659/en/
    Technavio has announced its latest market research report titled global breast biopsy devices market 2019-2023.
  • (Graphic: Business Wire)
    Read the 175-page report with TOC on Breast Biopsy Devices market research report by Product (biopsy needles and systems, biopsy image-guided systems, and others), Modality (stereotactic X-ray guided breast biopsy, ultrasound-guided breast biopsy, and MRI-guided breast biopsy), End-User (hospitals, ASCs, breast cancer specialty centers and clinics, and others), Geography (Asia, Europe, North America, and ROW), and the Segment Forecasts, 2019-2023.Breast Biopsy Devices Market Product Outlook (Revenue, USD Million, 2019-2023)
    Biopsy needles and systems was the largest segment of the global breast biopsy devices market in 2018.
  • Breast Biopsy Devices Market Regional Outlook (Revenue, USD Million, 2019-2023)
    North America was the largest geographical segment of the global breast biopsy devices market in 2018.

Global Liquid Biopsy & Other Non-Invasive Cancer Diagnostics Market, 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers

Retrieved on: 
Thursday, December 19, 2019
Medicine, Clinical medicine, Branches of biology, DNA, Medical signs, Biomarkers, Oncology, Liquid biopsy, Circulating tumor DNA, Biopsy, Circulating free DNA, Exosome

DUBLIN, Dec. 19, 2019 /PRNewswire/ -- The "Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Dec. 19, 2019 /PRNewswire/ -- The "Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers" report has been added to ResearchAndMarkets.com's offering.
  • In addition, it features an elaborate discussion on the likely future opportunity associated with such tests, over the next 10 years.
  • One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for non-invasive cancer diagnostics.
  • Amongst other promising diagnostic tools, liquid biopsy has emerged as a versatile and promising non-invasive cancer diagnostic tool.

Analysis on the World Market for Liquid Biopsy and Other Non-Invasive Cancer Diagnostics, 2019-2030 - Features Executive Insights from Key Industry Players - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 19, 2019
Surgery, Health, Oncology, Medicine, Clinical medicine, Medical specialties, Biopsy, Liquid biopsy, Medical diagnosis

In addition, it features an elaborate discussion on the likely future opportunity associated with such tests, over the next 10 years.

Key Points: 
  • In addition, it features an elaborate discussion on the likely future opportunity associated with such tests, over the next 10 years.
  • One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for non-invasive cancer diagnostics.
  • Amongst other promising diagnostic tools, liquid biopsy has emerged as a versatile and promising non-invasive cancer diagnostic tool.
  • In future, non-invasive cancer diagnosis methods, particularly liquid biopsies, are anticipated to replace the existing invasive diagnostic techniques.

IncellDx Signs Liquid Biopsy Distribution Agreement with Singapore-based Biolidics, Inc.

Retrieved on: 
Wednesday, December 18, 2019
Medicine, Medical specialties, Branches of biology, Anatomical pathology, PD-L1, Biopsy, Sarcoma, Oncology

SAN CARLOS,Calif., Dec. 18, 2019 /PRNewswire/ --IncellDx, Inc. and Biolidics have announced today that they have signed a Distribution Agreement for the IncellDx bioINK PD-L1 CTC Core Kit.

Key Points: 
  • SAN CARLOS,Calif., Dec. 18, 2019 /PRNewswire/ --IncellDx, Inc. and Biolidics have announced today that they have signed a Distribution Agreement for the IncellDx bioINK PD-L1 CTC Core Kit.
  • The IncellDx bioINK PD-L1 Core Kit is pre-optimized to enable highly sensitive and specific quantification of protein or mRNA expression on CTCs at a single-cell-by-cell resolution for microfluidic chips.
  • "We are very excited to expand our launch of our proprietary, optimized Liquid Biopsy reagent technology contained in our bioINK kits.
  • This agreement covers the first of many cancer specific bioINK kits including kits for breast cancer, lung cancer, urologic cancers, and sarcomas.